India  

42% patients experience freedom from oxygen dependence: DRDO scientist on 2-DG clinical trials

Video Credit: ANI - Duration: 01:59s - Published
42% patients experience freedom from oxygen dependence: DRDO scientist on 2-DG clinical trials

42% patients experience freedom from oxygen dependence: DRDO scientist on 2-DG clinical trials

Institute of Nuclear Medicine and Allied Sciences-DRDO scientist Dr Sudhir Chandna on drug 2-deoxy-D-glucose (2-DG) while speaking to ANI informed about the observations of the medicine's clinical trials.

"110 patients in ph 2 and 220 patients in ph 3 participated in clinical trials.

It has shown better efficacy in ph 2.

Recovery was 2-3 days faster for COVID patients.

Phase 3 data shows by day 3, freedom from oxygen dependence seen in 42% patients as compared to 31% patients who were in standard care," said Dr Sudhir Chandna.

Further referring to the data obtained he said that oxygen dependence reduced in a better way when we use this medicine along with standard care.

"The pricing will depend on the production and those factors are with Dr. Reddy's Laboratories who are our industry partners," said DRDO scientist.

On medicine's roll out, he said that it might come out in few days.


You Might Like


💡 newsR Knowledge: Other News Mentions

Defence Research and Development Organisation Defence Research and Development Organisation Government agency in India

DRDO invites EoI to transfer technology of 2-DG drug for bulk production

The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for treatment of Covid-19 patients, has called..
IndiaTimes

Contrary to vow, DRDO drug has steep price tag of Rs 990 a sachet

Contrary to promises that the indigenously developed Covid-19 drug 2-deoxy-D-glucose (2-DG) would be priced affordably to ensure it reaches as many patients as..
IndiaTimes
DRDO's new Covid-19 drug 2-DG: All you need to know, how effective is it? | Oneindia News [Video]

DRDO's new Covid-19 drug 2-DG: All you need to know, how effective is it? | Oneindia News

Institute of Nuclear Medicine and Allied Sciences and DRDO scientists conducted experiments with the help of the Center for Cellular and Molecular Biology and found that this molecule works effectively against Covid. Three phases of trials were conducted to ensure its efficacy. #2DG #Oraldrug #DRDO #Covid19 #INMAS

Credit: Oneindia    Duration: 01:24Published

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

COVID jabs to be made 'compulsory' for care home staff - Whitehall sources

The government is to make coronavirus vaccinations compulsory for care home staff who work with elderly and vulnerable people, Whitehall sources say.
Sky News

Jon Stewart's COVID Lab Rant Hurts Frontline Scientists, Says Dr. Peter Hotez

Jon Stewart going off about COVID-19 originating from a Chinese lab -- seemingly embracing that unproven theory -- could have a negative impact on scientists..
TMZ.com

Covid-19: At 63.8k, India sees slight rise in new cases; logs 1k+ deaths

After falling sharply on the previous day, daily Covid cases and deaths in India registered a slight rise on Tuesday. The country reported 63,868 fresh cases and..
IndiaTimes

Dr. Reddy's Laboratories Indian multinational pharmaceutical company

Sputnik V is stored at -18C: Dr Reddy's Lab Global Logistics' Head [Video]

Sputnik V is stored at -18C: Dr Reddy's Lab Global Logistics' Head

Sputnik V is a minus 18-degrees Celsius storage vaccine, informed Ravi Mathur, Global Logistics' Head, Dr Reddy's Laboratories after the Russian vaccines arrived in India on May 01."Sputnik V is a minus 18-degrees Celsius storage vaccine. We have created a state-of-the-art central warehouse that operates below minus 20-degrees Celsius. These are single-dose ampules, once taken out have to be administered within 30 mins," informed Head of global logistics at Dr. Reddy's lab.

Credit: ANI    Duration: 01:43Published
Sputnik V will be available in few weeks after statutory clearances: Dr Reddy's Lab CEO [Video]

Sputnik V will be available in few weeks after statutory clearances: Dr Reddy's Lab CEO

The Sputnik V vaccine will be available in a few weeks after statutory clearances, informed Deepak Sapra, CEO of Dr Reddy's Laboratories after the Russian vaccines arrived in India on May 01. "Today, we have received 1,50,000 doses of Sputnik V vaccine here in Hyderabad. The vaccine will be available in a few weeks after it has gone through statutory clearances. The price will also be announced then," said CEO Sapra.

Credit: ANI    Duration: 01:02Published
150,000 doses of Sputnik V have arrived in India on 1st May | Oneindia News [Video]

150,000 doses of Sputnik V have arrived in India on 1st May | Oneindia News

Sputnik V is the Russian made covid vaccine with an efficacy rate above 90%. 150,000 doses of Sputnik have arrived at Hyderabad in India on Saturday. The vaccines will be handed over to Dr Reddy's Laboratories, and soon to be distributed among the healthcare systems of the country. #covid19 #covid vaccines #SputnikV #Russia #Indiacovidcrisis

Credit: Oneindia    Duration: 01:01Published

Related videos from verified sources

DCGI approves DRDO's anti-COVID drug helpful in faster recovery [Video]

DCGI approves DRDO's anti-COVID drug helpful in faster recovery

Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to..

Credit: ANI     Duration: 02:44Published
DRDO installs oxygen plant in AIIMS Trauma Center [Video]

DRDO installs oxygen plant in AIIMS Trauma Center

DRDO is setting up oxygen plant in AIIMS Trauma Center on May 05. This plant has a capacity of 1000 liters of oxygen per minute and at a time it will cater to 190 patients. DRDO will be setting up five..

Credit: ANI     Duration: 02:36Published